{
    "Trade/Device Name(s)": [
        "Audit\u2122M MicroCVTM Protein Linearity Set"
    ],
    "Submitter Information": "Aalto Scientific, Ltd.",
    "510(k) Number": "K101216",
    "Predicate Device Reference 510(k) Number(s)": [
        "K042318"
    ],
    "Regulatory Class": "Class I",
    "Product Code(s)": [
        "JJY"
    ],
    "Summary Letter Date": "December 3, 2010",
    "Summary Letter Received Date": "December 7, 2010",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 862.1660"
    ],
    "Regulation Name(s)": [
        "Quality Control"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Alpha-1-Antitrypsin",
        "Complement C3",
        "Complement C4",
        "Immunoglobulin G",
        "Immunoglobulin A",
        "Immunoglobulin M",
        "Transferrin"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [
        ""
    ],
    "Instrument(s)/Platform(s)": [
        ""
    ],
    "Method(s)/Technology(ies)": [
        ""
    ],
    "Methodologies": [
        ""
    ],
    "Submission Type(s)": [
        "Quality control material"
    ],
    "Document Summary": "FDA 510(k) summary for Audit\u2122M MicroCVTM Protein Linearity Set, a serum-based multi-level quality control material for linearity assessment of seven protein analytes.",
    "Indications for Use Summary": "Intended to simulate human patient serum samples and detect systematic analytical deviations in laboratory testing procedures for specified protein analytes using quantitative assays.",
    "fda_folder": "Clinical Chemistry"
}